Book description
New and emerging directions in pharmaceutical research to better
treat schizophrenia
Although the dopamine hypothesis has been the cornerstone of
schizophrenia therapeutics, it is clear that dopamine-based approaches
do not treat all aspects of the disease. Moreover, many schizophrenia
patients fail to respond to current antipsychotics. Integrating
chemistry, biology, and pharmacology, this book explores emerging
directions in pharmaceutical research for drug targeting and discovery
in order to find more effective treatments for schizophrenia, one of
the most serious and widespread psychiatric diseases.
Targets and Emerging Therapies for Schizophrenia presents the
basics of schizophrenia, drug targets for the disease, and potential
new drugs and therapeutics. It begins with a discussion of prevalence
and etiology. Then, it describes therapies such as dopamine agonists
and phosphodiesterase (PDE) inhibitors as well as growing research
aimed at addressing untreated symptoms. Next, the authors discuss
receptor modulators, inhibitors, and targeting strategies for drug
discovery. Both the neurobiological and chemical aspects of all major
pharmacological targets are examined.
With contributions from an international team of pioneering
pharmaceutical researchers, this book compiles the current knowledge
in the field, setting the stage for new breakthroughs in the treatment
of schizophrenia. Targets and Emerging Therapies for Schizophrenia:
- Provides a comprehensive resource for neuro-drug discovery and
the development of molecular targets for schizophrenia treatment
- Draws from chemistry, biology, and pharmacology for more
effective drug targeting and discovery
- Explores a wide range of receptors and molecular targets,
including dopamine, PDEs, and neuropeptides
With Targets and Emerging Therapies for Schizophrenia as their
guide, drug discovery and development scientists have the information
they need to advance their own research so that new, more effective
treatments for schizophrenia will soon be a reality.
JEFFREY S. ALBERT, PhD, is a Project Leader and Head of Lead
Generation Chemistry in AstraZeneca's neuroscience department. He has
authored or coauthored more than forty publications, mostly focusing
on novel therapeutic targets involved in depression, schizophrenia,
and Alzheimer's disease and on the development and application of
fragment-based lead generation methodologies.
MICHAEL W. WOOD, PhD, is an External Collaborations Director in
AstraZeneca's neuroscience unit where he is responsible for
coordinating research to deliver novel therapeutics targeting
schizophrenia as well as other neuroscience treatments. He has been
focused on neuroscience drug discovery research for fifteen years.
